Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1565 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Improvement of Pain, Fatigue, and Disability in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials
Dafna D. Gladman¹, Vibeke Strand², Arthur Kavanaugh³, Philip J. Mease⁴, Christopher J. Edwards⁵, Maurizio Cutolo⁶, Frédéric Lioté⁷, Paul Bird⁸, Randall M. Stevens⁹, Lichen Teng⁹, Marla Hochfeld⁹ and Georg A. Schett¹⁰, ¹University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Stanford University, Portola Valley, CA, ³University of California San Diego, La Jolla, CA, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵University Hospital Southampton, Southampton, United Kingdom, ⁶Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁷Rheumatology Department, University Paris Diderot, Paris, France, ⁸Combined Rheumatology Practice, Kogarah, Australia, ⁹Celgene Corporation, Warren, NJ, ¹⁰Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis…
Abstract Number: 463 • 2014 ACR/ARHP Annual Meeting
Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double-Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis
Jonathan Kay¹, Roy Fleischmann², Edward C. Keystone³, Elizabeth C. Hsia^4,5, Neil Goldstein⁴, Benjamin Hsu⁴, Yiying Zhou⁴, Jürgen Braun⁶ and Arthur Kavanaugh⁷, ¹UMass Memorial Medical Center, Worcester, MA, ²Southwestern Medical Center, Department of Medicine, Metroplex Clinical Research Center, University of Texas, Dallas, TX, ³University of Toronto, Mount Sinai Hospital, Toronto, ON, Canada, ⁴Janssen Research & Development, LLC., Spring House, PA, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Rheumazentrum Ruhrgebiet, Herne, Germany, ⁷University of California San Diego, La Jolla, CA
Background/Purpose: To present an analysis of pooled data through approx 5yrs of follow-up from 5 completed golimumab(GLM) Ph3 SC trials across rheumatological indications. Methods: SC…
Abstract Number: 1564 • 2014 ACR/ARHP Annual Meeting
Long-Term (104-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial and Open-Label Extension
Philip J. Mease¹, Adewale O. Adebajo², Dafna D. Gladman³, Juan J. Gomez-Reino⁴, Stephan Hall⁵, Arthur Kavanaugh⁶, Eric Lespessailles⁷, Georg A. Schett⁸, Kamal Shah⁹, Randall M. Stevens⁹, Lichen Teng⁹ and Jürgen Wollenhaupt¹⁰, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²University of Sheffield, Sheffield, United Kingdom, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁵Cabrini Health and Monash University, Melbourne, Australia, ⁶University of California San Diego, La Jolla, CA, ⁷University of Orléans, Orléans, France, ⁸Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁹Celgene Corporation, Warren, NJ, ¹⁰Schön Klinik Hamburg Eilbek, Hamburg, Germany
Background/Purpose: Apremilast (APR), a phosphodiesterase 4 inhibitor, helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA). PALACE 1,…
Abstract Number: L1 • 2014 ACR/ARHP Annual Meeting
Secukinumab, a Human Anti-Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis: 24-Week Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo-Controlled Study Using Subcutaneous Dosing
Iain B. McInnes^1,2, Philip J. Mease³, Bruce Kirkham⁴, Arthur Kavanaugh⁵, Christopher T. Ritchlin⁶, Proton Rahman⁷, Désirée van der Heijde⁸, Robert B. M. Landewé⁹, Philip G. Conaghan¹⁰, Hanno Richards¹¹, Gregory Ligozio¹², Luminita Pricop¹³ and Shephard Mpofu¹⁴, ¹University of Glasgow, Glasgow, Scotland, ²University of Glasgow, Glasgow, United Kingdom, ³Swedish Medical Center and University of Washington, Seattle, WA, ⁴Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, ⁵UC San Diego School of Medicine, La Jolla, CA, ⁶Allergy Immunology & Rheumatology, University of Rochester Medical Center, Rochester, NY, ⁷Memorial University, St John's, NF, Canada, ⁸Leiden University Medical Center, Leiden, Netherlands, ⁹University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ¹⁰University of Leeds, Leeds, United Kingdom, ¹¹Clinical Immunology / Dermatology, Novartis Pharma AG, Basel, Switzerland, ¹²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹³Integrated Hospital Care (IHC) Franchise, Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a human anti–IL-17A monoclonal antibody, has shown efficacy in the treatment of psoriasis in phase 3 studies with subcutaneous (s.c.) dosing as well…
Abstract Number: 3010 • 2014 ACR/ARHP Annual Meeting
The Development and Evaluation of a Self-Monitoring and Patient-Initiated Follow-up Service for People with Rheumatoid or Psoriatic Arthritis on Methotrexate
Hayley McBain^1,2, Michael Shipley³, Abigail Olaleye³, Samantha Moore⁴, Shashi Hirani⁵ and Stanton Newman⁶, ¹Health Services Research and Management Division, City University London, London, United Kingdom, ²Community Health Newham, East London Foundation Trust, London, United Kingdom, ³University College Hospital London, London, United Kingdom, ⁴Rheumatology, University College London, London, United Kingdom, ⁵City University London, London, United Kingdom, ⁶School of Community & Health Sciences, City University London, London, United Kingdom
Background/Purpose: Patient-initiated services in rheumatology have been found to be cost-saving without compromising the clinical or psychosocial well-being of patients with rheumatoid arthritis. Self-monitoring is…
Abstract Number: 1579 • 2014 ACR/ARHP Annual Meeting
Change in Weight from Baseline with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
Philip J. Mease¹, Dafna D. Gladman², Arthur Kavanaugh³, Adewale O. Adebajo⁴, Juan Gomez-Reino⁵, Jurgen Wollenhaupt⁶, Georg A. Schett⁷, Kamal Shah⁸, ChiaChi Hu⁸, Randall M. Stevens⁸, Christopher Edwards⁹ and Charles A. Birbara¹⁰, ¹Rheumatology Research, Swedish Medical Center, Seattle, WA, ²University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of California San Diego, La Jolla, CA, ⁴University of Sheffield, Sheffield, United Kingdom, ⁵Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ⁶Schön-Klinik, Hamburg, Germany, ⁷Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Celgene Corporation, Warren, NJ, ⁹Tremona Road, NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom, ¹⁰University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR) is a PDE4 inhibitor that helps regulate the immune response. PALACE 1, 2, and 3 assessed the efficacy and safety of APR…
Abstract Number: L22 • 2014 ACR/ARHP Annual Meeting
Long-Term (104-Week) Safety and Efficacy of Monotherapy with Apremilast in DMARD-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (PALACE 4)
Alvin Wells¹, Christopher Edwards², Adewale O. Adebajo³, Alan J. Kivitz⁴, Paul Bird⁵, Kamal Shah⁶, ChiaChi Hu⁶, Randall M. Stevens⁶ and Jacob A. Aelion⁷, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²University Hospital Southampton, Southampton, United Kingdom, ³University of Sheffield, Sheffield, United Kingdom, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Combined Rheumatology Practice, Sydney, Australia, ⁶Celgene Corporation, Warren, NJ, ⁷West Tennessee Research Institute, Jackson, TN
Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes joint inflammation and other manifestations of psoriatic arthritis…
Abstract Number: 2970 • 2014 ACR/ARHP Annual Meeting
Psoriatic Arthritis is Associated with Heterotopic Ossification after Total Hip Arthroplasty
Mario Cedillo¹, Arielle Fein², Susan M. Goodman³, Rebecca Zhu⁴, Mark P. Figgie⁵, Michael Alexiades⁶, Jayme C. Burket⁷ and Lisa A. Mandl³, ¹Weill Cornell Medical College, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Rheumatology, Hospital for Special Surgery, New York, NY, ⁴Clinical Research, Hospital for Special Surgery, New York, NY, ⁵Orthopedics, Hospital for Special Surgery, New York, NY, ⁶Orthopaedics, Hospital for Special Surgery, New York, NY, ⁷Healthcare Research Institute, Hospital for Special Surgery, New York, NY
Background/Purpose: Heterotopic ossification (HO), the pathologic deposition of ectopic bone in soft tissues, is a feared complication of total hip arthroplasty (THA). HO is strongly…
Abstract Number: 1544 • 2014 ACR/ARHP Annual Meeting
Economic and Comorbidity Burden Among Moderate-to-Severe Psoriasis Patients Comorbid with Psoriatic Arthritis
Steven R Feldman¹, Yang Zhao², Lizheng Shi³, Jackie Lu² and MaryHelen Tran², ¹Wake Forest University School of Medicine, Winston-Salem, NC, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³Tulane University, New Orleans, LA
Background/Purpose: Psoriasis (PsO) and psoriatic arthritis (PsA) are associated with substantial economic and comorbidity burdens. However, the burden among PsO patients comorbid with PsA has…
Abstract Number: 2527 • 2014 ACR/ARHP Annual Meeting
The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts
Amandine Tubery¹, Cristel Castelli¹, Florence Erny¹, Françoise Barchechath-Flaisler¹, Sabrina Dadoun², Bruno Fautrel³ and Cecile Gaujoux Viala¹, ¹Nîmes University Hospital, Rheumatology Department, Nimes, France, ²Sorbonne Universités, UPMC Univ Paris 06, GRC-08, Institut Pierre Louis d’Epidémiologie et de Santé Publique, paris, France, ³Rheumatology, UPMC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France
Background/Purpose: The addition of biological agents in treatment strategies in chronic inflammatory arthritides have improved the possibility of controlling disease activity and slowing the progression…
Abstract Number: 1543 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in the Signs and Symptoms of Psoriatic Arthritis in DMARD-Naive Patients: Results from a Phase 3, Randomized, Controlled Trial
Alvin Wells¹, Adewale O. Adebajo², Jacob A. Aelion³, Paul Bird⁴, Alan Kivitz⁵, Frédéric Lioté⁶, Piercarlo Sarzi-Puttini⁷, ChiaChi Hu⁸, Randall M. Stevens⁸ and Christopher J. Edwards⁹, ¹Rheumatology & Immunotherapy Center, Franklin, WI, ²University of Sheffield, Sheffield, United Kingdom, ³West Tennessee Research Institute, Jackson, TN, ⁴Combined Rheumatology Practice, Kogarah, Australia, ⁵Altoona Arthritis & Osteoporosis Center, Duncansville, PA, ⁶Hôpital Lariboisière & University Paris Diderot, Paris, France, ⁷Rheumatology Unit, L. Sacco University Hospital, Milan, Italy, ⁸Celgene Corporation, Warren, NJ, ⁹University Hospital Southampton, Southampton, United Kingdom
Background/Purpose: Apremilast (APR), an oral phosphodiesterase 4 inhibitor, helps regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis (PsA). PALACE…
Abstract Number: 2423 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Synovitis Detected By Ultrasound in Rheumatoid Arthritis and Psoriatic Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
José M. Senabre-Gallego¹, José Rosas-Gómez de Salazar¹, Esteban Salas-Heredia¹, Gregorio Santos-Soler¹, Francisca Llinares-Tello², Carlos Santos-Ramirez³, Mabel Sánchez-Barrioluengo⁴, Xavier Barber-Vallés⁵, Rafaela Ortega³, Ana Pons¹, Catalina Cano¹ and Maria Luisa Lorente-Betoret¹, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ³Rheumatology, Hospital Marina Salud, Denia, Spain, ⁴Ingenio (CSIC-UPV), Universitat Politècnica de València, Valencia, Spain, ⁵Center of Operations Research, University Miguel Hernández, Elche, Spain
Background/Purpose To estimate the prevalence of subclinical synovitis detected by ultrasound in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients in clinical remission receiving anti-TNFα…
Abstract Number: 1550 • 2014 ACR/ARHP Annual Meeting
Prevalence of Enthesitis and Dactylitis, Impact on Disease Severity and Evolution over 12 Months in Psa Patients Treated with Anti-TNF in a Real-World Setting
Proton Rahman¹, Denis Choquette², William Bensen³, Majed Khraishi⁴, Saeed Shaikh⁵, Regan Arendse⁶, Isabelle Fortin⁷, Andrew Chow⁸, Maqbool Sheriff⁹, Eliofotisti Psaradellis¹⁰, John S. Sampalis¹⁰, Susan Otawa¹¹, Francois Nantel¹², Allen J Lehman¹¹ and May Shawi¹², ¹Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ²Rheumatology, Notre Dame Hospital, Montreal, QC, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Nexus Clinical Research, St John's, NF, Canada, ⁵McMaster University, Hamilton, ON, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷Centre de Rhumatologie de l'Est du Québec, Rimouski, QC, Canada, ⁸University of Toronto, McMaster University, Credit Valley Rheumatology, Mississauga, ON, Canada, ⁹Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹²Janssen Inc., Toronto, ON, Canada
Background/Purpose Spondyloarthritis, including psoriatic arthritis (PsA), is characterized by inflammatory arthritis affecting axial and peripheral joints. It is commonly associated with extra-articular and peri-articular manifestations…
Abstract Number: 2411 • 2014 ACR/ARHP Annual Meeting
Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in a Canadian Setting
John Kelsall¹, Algis Jovaisas², Proton Rahman³, Dalton Sholter⁴, Michael Starr⁵, William Bensen⁶, Maqbool Sheriff⁷, Wojciech Olszynski⁸, Michel Zummer⁹, Rafat Faraawi¹⁰, Andrew Chow¹¹, Suneil Kapur¹², Emmanouil Rampakakis¹³, John S. Sampalis¹³, Francois Nantel¹⁴, Susan Otawa¹⁵, May Shawi¹⁴ and Allen J Lehman¹⁵, ¹The Mary Pack Arthritis Centre, Vancouver, BC, Canada, ²194 Main Street, University of Ottawa, Ottawa, ON, Canada, ³Faculty of Medicine, Memorial University of Newfoundland, St. John's, NF, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁶St Josephs Hospital and McMaster University, Hamilton, ON, Canada, ⁷Nanaimo Regional General Hospital, Nanaimo, BC, Canada, ⁸University of Saskatchewan, Saskatoon, SK, Canada, ⁹Université de Montréal, Montreal, QC, Canada, ¹⁰Medicine, McMaster University, Hamilton, ON, Canada, ¹¹McMaster University, Hamilton and Credit Valley Hospital, Mississauga, ON, Canada, ¹²Rheumatology, University of Ottawa, Ottawa, ON, Canada, ¹³JSS Medical Research, Montreal, QC, Canada, ¹⁴Janssen Inc., Toronto, ON, Canada, ¹⁵Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: The efficacy of anti-TNF in the management of psoriatic arthritis (PsA) and rheumatoid arthritis (RA) has been demonstrated in numerous controlled clinical trials. The…
Abstract Number: 1561 • 2014 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, and the Impact of Baseline Weight and BMI on ACR20 and HAQ-DI Response: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
Georg A. Schett¹, Philip J. Mease², Dafna D. Gladman³, Arthur Kavanaugh⁴, Adewale O. Adebajo⁵, Juan J. Gomez-Reino⁶, Jurgen Wollenhaupt⁷, Maurizio Cutolo⁸, Eric Lespessailles⁹, ChiaChi Hu¹⁰, Randall M. Stevens¹⁰, Christopher J. Edwards¹¹ and Charles A. Birbara¹², ¹Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²Swedish Medical Center and University of Washington, Seattle, WA, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴University of California San Diego, La Jolla, CA, ⁵University of Sheffield, Sheffield, United Kingdom, ⁶Rheumatology, Hospital Clinico Universitario, Santiago, Spain, ⁷Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, ⁸Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ⁹University of Orléans, Orléans, France, ¹⁰Celgene Corporation, Warren, NJ, ¹¹University Hospital Southampton, Southampton, United Kingdom, ¹²University of Massachusetts Medical School, Worcester, MA
Background/Purpose: Apremilast (APR) is a phosphodiesterase 4 inhibitor that helps to regulate the immune response that causes inflammation and skin disease associated with psoriatic arthritis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].